Company Overview: PYC Therapeutics Limited (ASX: PYC) is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. Below are the key price indicators for the stock: This Report covers the Price Action, Technical Indicators Analysis along with the Stop Loss Levels, Target Prices, and Recommendation on this one stock.

ASX All Ordinaries Index (.AORD) Market Round-Up

The S&P/ASX All Ordinaries Index (.AORD) ended the week at 8,922.70, gaining 0.02%, as Australian equities remained largely steady amid mixed global market conditions. The market was influenced by developments in commodity prices, easing crude oil prices and changing expectations for domestic interest rates. Mining and gold-related stocks provided support, while weakness across several major sectors limited the broader advance. Investor attention remained focused on inflation risks and comments from the Reserve Bank of Australia, with expectations of further rate adjustments adding to market uncertainty

From a technical perspective, The S&P/ASX All Ordinaries Index closed at 8,919.10, remaining below its 21-day Simple Moving Average (SMA) at 9,114.36 and 50-day SMA at 9,162.82, indicating continued technical pressure. However, the index continues to trade above the key upward sloping trendline support near 8,880, keeping the broader technical structure intact. The 14-day Relative Strength Index (RSI) stands at 33.81, reflecting subdued momentum and remaining below the neutral 50 level. A sustained hold above the rising trendline could help stabilize the index, while a break below this level may increase downside pressure in the sessions ahead.

Past performance is not a reliable indicator of future performance.